Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Morepen Laboratories's Average Total Inventories for the quarter that ended in Jun. 2026 was ₹2,718 Mil. Morepen Laboratories's Revenue for the
three
months ended in Jun. 2026 was ₹5,701 Mil.
Morepen Laboratories's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.48.
Morepen Laboratories's Inventory-to-Revenue for the quarter that ended in Jun. 2026
declined
from Mar. 2026 (0.56) to Mar. 2026 (0.48)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Morepen Laboratories's Days Inventory for the
three
months ended in Jun. 2026 was 61.66.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Morepen Laboratories's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.48.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Morepen Laboratories's Days Inventory for the
three
months ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories Inventory-to-Revenue Related Terms
Morepen Laboratories Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS: Inventory-to-Revenue Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Inventory-to-Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Morepen Laboratories's Inventory-to-Revenue for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a Inventory-to-Revenue of 0.48 as of Jun. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Inventory-to-Revenue too high?
Morepen Laboratories' current Inventory-to-Revenue is 0.48. Overall, Morepen Laboratories has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Inventory-to-Revenue compare to ZTS?
Morepen Laboratories' Inventory-to-Revenue of 0.48 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Drug Manufacturers company?
A good Inventory-to-Revenue depends on the Drug Manufacturers industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Inventory-to-Revenue is 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹54.88, compared to a current price of ₹119.04 — trading 116.9% above its estimated fair value. The current Inventory-to-Revenue is 0.48. Morepen Laboratories' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Inventory-to-Revenue is 0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹119.04 is trading 116.9% above its estimated GF Value™ of ₹54.88.
GuruFocus considers Morepen Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Inventory-to-Revenue: 0.48
GF Value™: ₹54.88 vs. price of ₹119.04 (116.9% above fair value)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is an Indian pharmaceutical company engaged in the manufacture and sale of active pharmaceutical ingredients (APIs), formulations, and home health products. Its API portfolio includes products such as loratadine, atorvastatin, montelukast, and rosuvastatin, which are supplied to pharmaceutical companies in India and exported to regulated and emerging markets including the United States and Europe. The company also markets branded and generic formulations, over-the-counter remedies, and home health devices such as digital thermometers, blood pressure monitors, pulse oximeters, and glucometers, sold under its own brands through retail pharmacies and distributors. It operates primarily in the pharmaceuticals segment, with additional revenue from its home health and diagnostics business. Morepen generates revenue from API sales, domestic formulation sales, exports, and consumer health product sales, with India contributing the largest share of revenue and exports accounting for the remainder.
64GF Score
Get the complete analysis for NSE:MOREPENLAB
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
